APC/Cyanine7 anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_APCCyanine7_CD4_Antibody_032019_updated.png
Human peripheral blood lymphocytes stained with CD4 (clone OKT4) APC/Cyanine7 (filled histogram) or Mouse IgG2b, κ isotype control (open histogram).
  • OKT4_APCCyanine7_CD4_Antibody_032019_updated.png
    Human peripheral blood lymphocytes stained with CD4 (clone OKT4) APC/Cyanine7 (filled histogram) or Mouse IgG2b, κ isotype control (open histogram).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
317417 25 tests 100€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317450 100 µg 184€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317418 100 tests 249€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For flow cytometric staining using the µg size, the suggested use of this reagent is =0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Additional Product Notes
BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. He WT, et al. 2022. Sci Transl Med. 14:eabl9605. PubMed
  2. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  3. Zhang M, et al. 2023. JCI Insight. 8: . PubMed
  4. Wang P, et al. 2023. Front Immunol. 13:1104329. PubMed
  5. Gilman KE, et al. 2023. Front Immunol. 13:1045710. PubMed
  6. Chung Y, et al. 2014. J Vis Exp. 89: 51660. PubMed
  7. Ivan Jelcic et al. 2018. Cell. 175(1):85-100 . PubMed
  8. García-Broncano P, et al. 2020. J Infect. 80:99. PubMed
  9. Zhou X, et al. 2021. Cell Reports. 35(6):109109. PubMed
  10. Sampedro-Nuñez M, et al. 2018. Sci Rep. 8:17812. PubMed
  11. Ho CH, et al. 2021. Arthritis Res Ther. 23:199. PubMed
  12. Wang H, et al. 2022. Front Immunol. 13:852436. PubMed
  13. Pino M, et al. 2022. Nat Commun. 13:5055. PubMed
  14. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  15. Hoang TN, et al. 2021. Cell. 184:460. PubMed
  16. Pino M, et al. 2020. Front Immunol. 11:1275. PubMed
  17. Palamides P, et al. 2016. Dis Model Mech. 9: 985 - 997. PubMed
  18. Cicin-Sain L, et al. 2010. J Immunol. 184:6739. PubMed
  19. Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed
  20. Boyle M, et al. 2015. PLoS Pathog. 11: 1005041. PubMed
  21. Tatovic D, et al. 2015. J Immunol. 195: 386 - 392. PubMed
  22. Song G, et al. 2020. bioRxiv. . PubMed
  23. Hoang TN, et al. 2020. bioRxiv. . PubMed
  24. Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed
  25. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  26. Leclercq G, et al. 2021. J Immunother Cancer. 9: . PubMed
  27. Bäcker-Koduah P, et al. 2020. Ann Clin Transl Neurol. 1.422222222. PubMed
  28. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  29. Sureshchandra S, et al. 2022. Cell Rep. 39:110938. PubMed
  30. He WT, et al. 2022. Nat Immunol. 23:960. PubMed
  31. Harper JL, et al. 2020. Nat Med. 519:26. PubMed
  32. Moore T,et al. 2017. Cancer Immunol Immunother. . 10.1007/s00262-017-2073-0. PubMed
  33. Franco LM, et al. 2019. J Exp Med. 216:384. PubMed
  34. Ostadkarampour M, et al. 2016. PLoS One. 11:e0164751. PubMed
  35. Xue J, et al. 2013. PLoS One. 8:72295. PubMed
  36. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  37. Zhao F, et al. 2020. Cell Rep. 32:108122. PubMed
  38. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
  39. Wu B, et al. 2022. Nat Commun. 13:2155. PubMed
  40. Chen YP, et al. 2020. Cell Res. 30:1024. PubMed
  41. Su C, et al. 2020. Nat Commun. 2.745833333. PubMed
  42. Groen B, et al. 2015. Sci Rep. 5: 13618. PubMed
  43. Kim N, et al. 2020. Nat Commun. 2.045138889. PubMed
  44. Yost KE, et al. 2019. Nat Med. 25:1251. PubMed
  45. Chowdhury A, et al. 2015. J Virol. 89: 8677-8686. PubMed
RRID
AB_571946 (BioLegend Cat. No. 317417)
AB_2687202 (BioLegend Cat. No. 317450)
AB_571947 (BioLegend Cat. No. 317418)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 7    Revision Date: 03/20/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account